Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Serratus Posterior Superior Intercostal Plane Block Versus Erector Spinae Plane Block in Thoracic Spine Surgeries

9 giugno 2026 aggiornato da: Mohamed Zakarea Wfa, Tanta University

Spinal surgeries coincide with high level of pain due to extensive dissection and muscle retraction so inadequate pain control delays patient recovery, rehabilitation and also is an important source of patient dissatisfaction [1].

Non-steroidal anti-inflammatory drugs and opioids are used to control pain post spine surgeries. The side effects of opioids are nausea and vomiting (PONV), delirium, sedation, constipation, tolerance, respiratory depression, and high dependence [2]. Many efforts done by different studies to decrease the length of hospital stay and the dependence on opioids by using multimodal analgesic modalities including regional blocks by injection of local anesthesia before skin incision to block the pain pathway from the start. [3] The SPSM originates from C7-T2 (sometimes T3) spinous processes, progressing obliquely and inserting on the lateral of the second to fifth ribs' angle , The Serratus Posterior Superior Intercostal Plane Block (SPSIPB) first described by Tulgar et al,[4] is a novel interfascial plane block that involves the injection of a local anesthetic between the Serratus posterior superior and intercostal muscles, dermatomal analysis of the patients showed sensory block reached the C3 dermatome in all patients in the cephalic direction. In the caudal direction, it was determined that sensory block reached at least the T7 dermatome in all patients.

Erector spinae plane (ESP) block first described in 2016 by Forero et al. [5], it is a truncal block which inject (LA) between the thoracic transverse process and erector spinae muscle and spread to the thoracic paravertebral space thereby targeting the dorsal and ventral rami of spinal nerves [6]. Because they may provide an alternative to thoracic paravertebral blocks with fewer risks of pneumothorax, it is used to provide postoperative analgesia for thoracic and spine surgeries. And also used to manage chronic pain such as complex regional pain syndrome and failed back surgery syndrome [2].

Aim of the work:

Compare the efficacy of serratus posterior superior intercostal plane block versus erector spinae plane block in thoracic spine surgeries at the level between T1 to T7 Primary outcome: NRS (Numerical rating scale) Secondary outcome: 1st dose of rescue analgesia, total doses of rescue analgesia, motor block, and 1st time of ambulation

Patients and methods:

This randomized double-blinded study will be carried out on 60 adult patients of both sexes undergoing elective thoracic spine surgeries in Tanta University Hospitals for a period of from April 2026 to December 2026.

Informed written consent will be obtained from the parents. They will receive an explanation of the purpose of the study, and every patient will have a secret code number. All data of the patients will be confidential with secret codes and private files for each patient; all given data will be used for current medical research only.

Any unexpected risks that appeared during the research will be cleared to the participants and ethical committee on time. Investigator who is blinded to group allocation provided postoperative care and assessments.

Inclusion Criteria: adult patients of both sexes undergoing elective thoracic spine surgeries aged from 18 years to 60 years, ASA I or II, thoracic levels between T1 to T7

Exclusion Criteria:

Parents refusal. Coagulopathy. Allergy to local anesthesia. Local infection at the site of injection. Pregnancy. Sever motor deficit (grade < 2) and sever sensory deficit (grade < 1).

Randomization and blindness:

Computer-generated randomization numbers will be used for random allocation and each patients' code will be kept in an opaque sealed envelope. Patients will be randomly allocated with 1:1 allocation ratio into three groups in a parallel manner:

  • Group S (n=35): Serratus Posterior Superior Intercostal Plane Block will receive 30 ml of 0.25% bupivacaine on each side.
  • Group E (n=35): erector spinae block group will receive 20 ml of 0.25% bupivacaine on each side.

Methods:

  1. Preoperative:

    Medical and surgical history of the patients will be taken, clinical examination of the patients will be performed and routine laboratory investigations such as CBC, and coagulation studies.

  2. Intraoperative:

Monitoring (non-invasive blood pressure, pulse oximetry, electrocardiogram and temperature probe) will be applied during induction and maintenance of anesthesia. No premedication will be administered. The intravenous line will be inserted, give preload crystalloid 500 ml, preoxygenation 5 minutes with 80% oxygen. Anesthesia will be induced by injection fentanyl 1mic/kg, xylocaine 1mg/kg, propofol 1-2 mg/kg, and atracurium 0.5 mg/kg, ventilation with mask for 3 minutes then intubation using armored tube. Anesthesia will be maintained with isoflurane, O2 to Air 50%: 50%, be sure adequate preload and adequate blood pressure then change the position of patients from supine to prone position, take precaution of prone position and make sure

Panoramica dello studio

Descrizione dettagliata

Spinal surgeries coincide with high level of pain due to extensive dissection and muscle retraction so inadequate pain control delays patient recovery, rehabilitation and also is an important source of patient dissatisfaction [1].

Non-steroidal anti-inflammatory drugs and opioids are used to control pain post spine surgeries. The side effects of opioids are nausea and vomiting (PONV), delirium, sedation, constipation, tolerance, respiratory depression, and high dependence [2]. Many efforts done by different studies to decrease the length of hospital stay and the dependence on opioids by using multimodal analgesic modalities including regional blocks by injection of local anesthesia before skin incision to block the pain pathway from the start. [3] The SPSM originates from C7-T2 (sometimes T3) spinous processes, progressing obliquely and inserting on the lateral of the second to fifth ribs' angle , The Serratus Posterior Superior Intercostal Plane Block (SPSIPB) first described by Tulgar et al,[4] is a novel interfascial plane block that involves the injection of a local anesthetic between the Serratus posterior superior and intercostal muscles, dermatomal analysis of the patients showed sensory block reached the C3 dermatome in all patients in the cephalic direction. In the caudal direction, it was determined that sensory block reached at least the T7 dermatome in all patients.

Erector spinae plane (ESP) block first described in 2016 by Forero et al. [5], it is a truncal block which inject (LA) between the thoracic transverse process and erector spinae muscle and spread to the thoracic paravertebral space thereby targeting the dorsal and ventral rami of spinal nerves [6]. Because they may provide an alternative to thoracic paravertebral blocks with fewer risks of pneumothorax, it is used to provide postoperative analgesia for thoracic and spine surgeries. And also used to manage chronic pain such as complex regional pain syndrome and failed back surgery syndrome [2].

Aim of the work:

Compare the efficacy of serratus posterior superior intercostal plane block versus erector spinae plane block in thoracic spine surgeries at the level between T1 to T7 Primary outcome: NRS (Numerical rating scale) Secondary outcome: 1st dose of rescue analgesia, total doses of rescue analgesia, motor block, and 1st time of ambulation

Patients and methods:

This randomized double-blinded study will be carried out on 60 adult patients of both sexes undergoing elective thoracic spine surgeries in Tanta University Hospitals for a period of from April 2026 to December 2026.

Informed written consent will be obtained from the parents. They will receive an explanation of the purpose of the study, and every patient will have a secret code number. All data of the patients will be confidential with secret codes and private files for each patient; all given data will be used for current medical research only.

Any unexpected risks that appeared during the research will be cleared to the participants and ethical committee on time. Investigator who is blinded to group allocation provided postoperative care and assessments.

Inclusion Criteria: adult patients of both sexes undergoing elective thoracic spine surgeries aged from 18 years to 60 years, ASA I or II, thoracic levels between T1 to T7

Exclusion Criteria:

Parents refusal. Coagulopathy. Allergy to local anesthesia. Local infection at the site of injection. Pregnancy. Sever motor deficit (grade < 2) and sever sensory deficit (grade < 1).

Randomization and blindness:

Computer-generated randomization numbers will be used for random allocation and each patients' code will be kept in an opaque sealed envelope. Patients will be randomly allocated with 1:1 allocation ratio into three groups in a parallel manner:

  • Group S (n=35): Serratus Posterior Superior Intercostal Plane Block will receive 30 ml of 0.25% bupivacaine on each side.
  • Group E (n=35): erector spinae block group will receive 20 ml of 0.25% bupivacaine on each side.

Methods:

  1. Preoperative:

    Medical and surgical history of the patients will be taken, clinical examination of the patients will be performed and routine laboratory investigations such as CBC, and coagulation studies.

  2. Intraoperative:

    Monitoring (non-invasive blood pressure, pulse oximetry, electrocardiogram and temperature probe) will be applied during induction and maintenance of anesthesia. No premedication will be administered. The intravenous line will be inserted, give preload crystalloid 500 ml, preoxygenation 5 minutes with 80% oxygen. Anesthesia will be induced by injection fentanyl 1mic/kg, xylocaine 1mg/kg, propofol 1-2 mg/kg, and atracurium 0.5 mg/kg, ventilation with mask for 3 minutes then intubation using armored tube. Anesthesia will be maintained with isoflurane, O2 to Air 50%: 50%, be sure adequate preload and adequate blood pressure then change the position of patients from supine to prone position, take precaution of prone position and make sure there is no compression on eye. nose. breast, chest, abdomen, genitalia, knee and dorsum of foot, avoid over abduction of upper limbs more than 90 degrees and take care of brachial plexus and radial nerves.

    In group S: patients in prone position, the skin will be sterilized with betadine 10% at the site of needle entry A linear probe will be placed near the medial border of the scapula and using the in-plane technique a 22-G, 80-mm block needle will be inserted between the third rib and the SPSm will be confirmed by injecting 0.5-1 ml of saline and observing the fluid lifting the serratus superior posterior muscle , 30 ml of 0.25% bupivacaine will be injected on each side .

    In group E: patients in prone position. Using strict sterilization techniques, the skin will be sterilized with betadine 10 % at the site of needle entry. The level of the thoracic vertebrae at which surgery will be proceeded will be determined on ultrasound and the block will cover 2 levels above and 2 levels below. The linear probe will be placed at the mid-vertebral line in the sagittal plane. The transducer will be shifted 3.5-4 cm laterally from midline to the surgical side to visualize the erector spinae muscle and transverse process. Using the in-plane technique, a 22-G, 80-mm block needle will be advanced until the transverse process will be reached. The correct location of the needle tip in the fascial plane deep to the erector spinae muscle will be confirmed by injecting 0.5-1 ml of saline and observing the fluid lifting the erector spinae muscle off the transverse process while avoiding muscle distension (hydro dissection). Once the needle will be at the correct location, a negative aspiration test will be confirmed. Bupivacaine 0.25% at a dose of20 ml will be then injected on each side.

    Surgery will be initiated 15-20 minutes after performing the blocks, follow up hemodynamic changes intraoperative, using BSI and maintain the level to be between 40-60 %, paracetamol 1gm will be given.

  3. postoperatively: patients will be extubated after returning the position to supine position, shifted to PACU, another investigator who will be blinded to group allocation provided postoperative care and assessments. Morphine will be given as rescue analgesia in a dose of 0.05 mg /kg.

Measurements:

All the following data will be collected:

Demographic data: age, sex, weight, ASA class. Hemodynamic parameter (MAP- Heart rate) Motor functions will be assessed using the following muscle power scale from 0-5 at (PACU- 1h, 2h, 4h,8h,16h and 24h postoperatively) Total doses of morphine as a rescue analgesia. First dose of morphine as a rescue analgesia in dose of 0.05 mg/kg. NRS (numerical rating scale) (PACU- 1h, 2h, 4h,8h,16h and 24h postoperatively)

1st time of ambulation. Adverse events: hypotension, hematoma, infection and LAST.

Tipo di studio

Interventistico

Iscrizione (Stimato)

70

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • State/Province:*
      • Tanta, State/Province:*, Egitto, 0020
        • Tanta University

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto

Accetta volontari sani

Descrizione

Inclusion Criteria:

- Inclusion Criteria: adult patients of both sexes undergoing elective thoracic spine surgeries aged from 18 years to 60 years, ASA I or II, thoracic levels between T1 to T7

Exclusion Criteria:

Parents refusal. Coagulopathy. Allergy to local anesthesia. Local infection at the site of injection. Pregnancy. Sever motor deficit (grade < 2) and sever sensory deficit (grade < 1).

Exclusion Criteria:

-

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Altro
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Triplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Group Serratus Posterior Superior Intercostal Plane Block
Serratus Posterior Superior Intercostal Plane Block Versus Erector Spinae Plane Block
Serratus Posterior Superior Intercostal Plane Block will receive 30 ml of 0.25% bupivacaine on each side.
Sperimentale: Group erector spinae block
Erector spinae block
Blocco erettore spinale

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Lasso di tempo
NRS (Numerical rating scale)
Lasso di tempo: 2 months to 4 months
2 months to 4 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
2ndry outecomes
Lasso di tempo: 2 months for 4 months

Hemodynamic changes( blood pressure in mm/hg and heart rate beats/min ) Body weight in Kg ASA Age in years 1st dose of rescue analgesia in mg total doses of rescue analgesia in mg motor block

1st time of ambulation in hour

2 months for 4 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

20 maggio 2026

Completamento primario (Stimato)

20 novembre 2026

Completamento dello studio (Stimato)

30 dicembre 2026

Date di iscrizione allo studio

Primo inviato

5 giugno 2026

Primo inviato che soddisfa i criteri di controllo qualità

9 giugno 2026

Primo Inserito (Effettivo)

12 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 giugno 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 giugno 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 36265PR46/5/26

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Blocco erettore spinale

Sottoscrivi